Empagliflozin 25 mg [clinicaltrials_resource:NCT00789035/group/P4]
Patients receive 25 mg Empagliflozin in tablets once daily.
participant flow for clinicaltrials:NCT00789035 [clinicaltrials_resource:2cd9b783b8f9863d460045b3c9a9be22]participant counts in P4 for milestone 2 of NCT00789035 [clinicaltrials_resource:NCT00789035/milestone/1/p/4]participant counts in P4 for milestone 3 of NCT00789035 [clinicaltrials_resource:NCT00789035/milestone/2/p/4]participant counts in P4 for milestone 4 of NCT00789035 [clinicaltrials_resource:NCT00789035/milestone/3/p/4]Adverse Event [clinicaltrials_resource:NCT00789035/withdraw/1]Lack of Efficacy [clinicaltrials_resource:NCT00789035/withdraw/2]Protocol Violation [clinicaltrials_resource:NCT00789035/withdraw/3]Withdrawal by Subject [clinicaltrials_resource:NCT00789035/withdraw/4]Other reason not defined above [clinicaltrials_resource:NCT00789035/withdraw/5]
group [clinicaltrials_vocabulary:group]
Empagliflozin 25 mg [clinicaltrials_resource:NCT00789035/group/P4]
Patients receive 25 mg Empagliflozin in tablets once daily.
Bio2RDF identifier
NCT00789035/group/P4
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00789035/group/P4
group id [clinicaltrials_vocabulary:group-id]
description
Patients receive 25 mg Empagliflozin in tablets once daily.
@en
identifier
clinicaltrials_resource:NCT00789035/group/P4
title
Empagliflozin 25 mg
@en
type
label
Empagliflozin 25 mg [clinicaltrials_resource:NCT00789035/group/P4]
@en